GlassScriptPhysician profile
Jerome P Schartman
NPI 1912113069
$30,222.64
in general payments reported to CMS, 2019-2025
23 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 76% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,317 · 2020: $1,408 · 2021: $5,663 · 2022: $17K · 2023: $1,259 · 2024: $1,090 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,486.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $24,900.95 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $1,455.43 | 2019-2025 | Eylea Hd, Eylea |
| Dutch Ophthalmic, USA | $514.77 | 2019-2024 | Tissueblue, Eva, Combined Machine |
| Alimera Sciences, INC. | $478.27 | 2019-2024 | Iluvien, Yutiq |
| Abbvie INC. | $435.34 | 2022-2025 | Ozurdex |
| Allergan, INC. | $424.65 | 2019-2021 | |
| Genentech USA, INC. | $411.05 | 2019-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $378.60 | 2022-2025 | Syfovre |
| Alcon Vision LLC | $184.08 | 2023-2024 | Hydrus Microstent, Clareon |
| Eyepoint US, INC. | $182.27 | 2019-2022 | |
| Astellas Pharma US INC | $180.44 | 2023-2025 | Izervay |
| Coherus Oncology, INC. | $173.57 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $141.24 | 2022-2025 | Xipere, Retisert, Visudyne |
| Ani Pharmaceuticals, INC. | $103.01 | 2025 | Iluvien, Yutiq |
| Rayner Intraocular Lenses Limited | $44.89 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $44.50 | 2025 | Triesence, Iheezo |
| Biogen, INC. | $43.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $40.00 | 2019-2020 | |
| Carl Zeiss Meditec USA, INC. | $30.31 | 2025 | |
| Neurotech Pharmaceuticals, INC. | $17.60 | 2025 | |
| Mallinckrodt Hospital Products INC. | $14.13 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.30 | 2021 | |
| Sun Pharmaceutical Industries INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$80,024.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Schartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.